Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age [0.03%]
配对乳腺癌样本之间21基因复发评分的不一致与患者年龄呈反比关系
Sarah M Bernhardt,Pallave Dasari,Joseph Wrin et al.
Sarah M Bernhardt et al.
Background: The Oncotype DX 21-gene Recurrence Score is a genomic-based algorithm that guides adjuvant chemotherapy treatment decisions for women with early-stage, oestrogen receptor (ER)-positive breast cancer. However, ...
Clinical implications of prospective genomic profiling of metastatic breast cancer patients [0.03%]
转移性乳腺癌患者预期基因组分析的临床含义
Courtney T van Geelen,Peter Savas,Zhi Ling Teo et al.
Courtney T van Geelen et al.
Background: Metastatic breast cancer remains incurable. Next-generation sequencing (NGS) offers the ability to identify actionable genomic alterations in tumours which may then be matched with targeted therapies, but the ...
Xue Chao,Lili Liu,Peng Sun et al.
Xue Chao et al.
Background: Metaplastic breast carcinoma (MBC) is a rare histological type of breast cancer, which commonly shows resistance to standard therapies and is associated with poor prognosis. The immune microenvironment in MBC ...
Targeting activated PI3K/mTOR signaling overcomes acquired resistance to CDK4/6-based therapies in preclinical models of hormone receptor-positive breast cancer [0.03%]
靶向激活的PI3K/mTOR信号克服了激素受体阳性乳腺癌前临床模型中对CDK4/6基础疗法产生的获得性抵抗
Neil A O&#x;Brien,Martina S J McDermott,Dylan Conklin et al.
Neil A O&#x;Brien et al.
Background: Combined targeting of CDK4/6 and ER is now the standard of care for patients with advanced ER+/HER2- breast cancer. However, acquired resistance to these therapies frequently leads to disease progression. As s...
Mary V Diaz-Santana,Katie M O&#x;Brien,Aimee A D&#x;Aloisio et al.
Mary V Diaz-Santana et al.
Background: Perinatal factors have been associated with some adult health outcomes, but have not been well studied in young-onset breast cancer. We aimed to evaluate the association between young-onset breast cancer and p...
HER2 expression on tumor-derived extracellular vesicles and circulating tumor cells in metastatic breast cancer [0.03%]
转移性乳腺癌中来自肿瘤的细胞外囊泡和循环肿瘤细胞上的HER2表达分析
Afroditi Nanou,Leonie Laura Zeune,Francois-Clement Bidard et al.
Afroditi Nanou et al.
Background: Tumor-derived extracellular vesicles (tdEVs) and circulating tumor cells (CTCs) in the blood of metastatic cancer patients associate with poor outcomes. In this study, we explored the human epidermal growth fa...
MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer [0.03%]
MDM2抑制与内分泌治疗以及CDK4 / 6抑制联用治疗ER阳性乳腺癌
Neil Portman,Heloisa H Milioli,Sarah Alexandrou et al.
Neil Portman et al.
Background: Resistance to endocrine therapy is a major clinical challenge in the management of oestrogen receptor (ER)-positive breast cancer. In this setting, p53 is frequently wildtype and its activity may be suppressed...
Targetable ERBB2 mutation status is an independent marker of adverse prognosis in estrogen receptor positive, ERBB2 non-amplified primary lobular breast carcinoma: a retrospective in silico analysis of public datasets [0.03%]
靶向ERBB2突变状态是雌激素受体阳性，ERBB2非扩增性原发性小叶乳腺癌不良预后的独立标志物：公共数据集的回顾性计算机分析
Sasagu Kurozumi,Mansour Alsaleem,Cíntia J Monteiro et al.
Sasagu Kurozumi et al.
Background: Invasive lobular carcinoma (ILC) accounts for 10-15% of primary breast cancers and is typically estrogen receptor alpha positive (ER+) and ERBB2 non-amplified. Somatic mutations in ERBB2/3 are emerging as a tr...
Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance [0.03%]
ESR1-CCDC170基因融合在乳腺癌内分泌耐药中的治疗作用
Li Li,Ling Lin,Jamunarani Veeraraghavan et al.
Li Li et al.
Background: Endocrine therapy is the most common treatment for estrogen receptor (ER)-positive breast cancer, but its effectiveness is limited by high rates of primary and acquired resistance. There are likely many geneti...
EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer [0.03%]
EFFECT：作为老年乳腺癌患者一线治疗的两种剂量紫杉醇纳米颗粒的疗效和功能影响的随机二期研究
Laura Biganzoli,Saverio Cinieri,Rossana Berardi et al.
Laura Biganzoli et al.
Background: Limited data are available regarding the use of nab-paclitaxel in older patients with breast cancer. A weekly schedule is recommended, but there is a paucity of evidence regarding the optimal dose. We evaluate...